Save 70% on brand and 90% with generic Tasigna
Information about Tasigna (Nilotinib)
Tasigna is a prescription medication that contains the active ingredient nilotinib, which is used to treat certain types of leukemia. It is classified as a tyrosine kinase inhibitor and works by targeting and blocking the BCR-ABL protein that causes the abnormal growth of cancer cells in chronic myelogenous leukemia (CML). By inhibiting this protein, Tasigna helps slow down the growth of leukemia cells.
Product Highlights
- Tasigna is primarily used to treat Philadelphia chromosome-positive CML in adult patients who are newly diagnosed or those who have not responded to previous therapies, including imatinib (Gleevec).
- It is also indicated for patients with CML in the accelerated phase, where the disease progresses more rapidly and requires more aggressive treatment.
Key Ingredient
Key Benefits
- Tasigna is highly effective in treating chronic myelogenous leukemia, particularly in patients who are resistant or intolerant to other therapies.
- By inhibiting the BCR-ABL protein, Tasigna selectively targets the underlying cause of CML, which may result in fewer side effects compared to traditional chemotherapy.
- Tasigna is taken orally in the form of tablets, making it a convenient treatment option for patients compared to intravenous therapies.
Direction of Use
- The standard dosage of Tasigna for newly diagnosed chronic phase CML is 300 mg taken twice daily. In the accelerated phase of CML, the dosage may vary, and patients are closely monitored for side effects.
- Tasigna tablets should be taken on an empty stomach, at least 2 hours after a meal and 1 hour before the next meal. The tablets should be taken whole, without crushing or chewing.
- For optimal results, it is important to take Tasigna at the same time each day and not miss doses. If you miss a dose, take it as soon as you remember, unless it’s almost time for your next dose. Do not take two doses at once.
Safety Concerns
- Common side effects include nausea, fatigue, headache, rash, diarrhea, and elevated liver enzymes. More severe side effects can include heart problems (e.g., QT prolongation), low blood counts, and liver damage.
- Tasigna can cause a prolonged QT interval, which may increase the risk of serious heart arrhythmias. Heart monitoring may be required, especially for patients with pre-existing heart conditions.
- Patients should have regular blood tests to monitor for changes in blood counts, liver function, and cholesterol levels, as Tasigna can cause low blood cell counts and elevated liver enzymes.
- Tasigna can interact with other medications, particularly those that affect heart rhythm, such as antiarrhythmics or certain antibiotics, and drugs that alter liver enzyme activity. It is important to let your healthcare provider know about all the medications you are taking.
Avoid Tasigna (Nilotinib) If
- If you have a known allergy to nilotinib or any of its ingredients, you should avoid taking Tasigna.
- Tasigna is contraindicated in patients with a history of QT prolongation, certain heart conditions, or those who are taking medications that prolong the QT interval.
- If you have severe liver dysfunction, Tasigna should be avoided, as it can exacerbate liver problems.
- Tasigna should not be used during pregnancy or while breastfeeding, as it may harm the fetus or infant. Effective contraception should be used during treatment, and women should avoid breastfeeding.
- If you have severe neutropenia, thrombocytopenia, or anemia, Tasigna should not be used without careful consideration and monitoring by a healthcare provider.
- Avoid Tasigna if you are taking medications that significantly interact with it, especially those that affect the liver enzyme CYP3A4 or prolong the QT interval.
